비피도박테리움 락티스 BB-12
Bifidobacterium lactis BB-12
📚 관련 논문 (16편)
1. Nutrients. 2021 Jan 9;13(1):192. doi: 10.3390/nu13010192. Probiotics for Preventing Necrotizing Enterocolitis in Preterm Infants: A Network Meta-Analysis. Beghetti I(1), Panizza D(1), Lenzi J(2), Gori D(2), Martini S(1), Corvaglia L(1), Aceti A(1). Author information: (1)Neonatal Intensive C
2. Pediatr Res. 2023 Oct;94(4):1480-1487. doi: 10.1038/s41390-023-02560-y. Epub 2023 Apr 5. The preterm gut microbiota and administration routes of different probiotics: a randomized controlled trial. Rahkola EN(1)(2), Rautava S(3)(4), Hiltunen H(3)(5), Ross C(6), Lahti L(6), Isolauri E(3)(5).
3. Int J Antimicrob Agents. 2022 Jan;59(1):106471. doi: 10.1016/j.ijantimicag.2021.106471. Epub 2021 Oct 29. A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial. Tsilika M(1), Thoma G(2), Aidoni Z(2), Tsaousi G(2), Fot
4. Curr Oncol. 2021 Dec 7;28(6):5192-5214. doi: 10.3390/curroncol28060435. Probiotics Evaluation in Oncological Surgery: A Systematic Review of 36 Randomized Controlled Trials Assessing 21 Diverse Formulations. Cogo E(1), Elsayed M(1), Liang V(1), Cooley K(1)(2)(3)(4), Guerin C(1), Psihogios A(1
1. J Gastroenterol Hepatol. 2026 Jan;41(1):140-154. doi: 10.1111/jgh.70137. Epub 2025 Nov 18. Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial. Ghoshal UC(1)(2), Ramakrishna BS(3), Rathi PM(4), Shukla A(5), Panigrahi MK(6), Jain S(4), Saha I(7), Chakravartty K(8), Singh M(1), Mustafa U(1)(2), Sahu S(1), Ghoshal U(9)(10), Chandnani S(4), Goenka MK(2), Mitra M(11). Author information: (1)Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. (2)Institute of Gastrosciences & Liver Transplantation, Apollo Multispeciality Hospitals, Kolkata, India. (3)Department of Gastroenterology, SRM Institutes of Medical Sciences (SIMS Hospital), Chennai, India. (4)Department of Gastroenterology, Topiwala National Medical College & BYL Nair Charitable Hospital, Mumbai, India. (5)Department of Gastroenterology, Seth G S Medical College and KEM Hospital, Mumbai, India. (6)Department of Gastroenterology, All India Institute of Medical Science, Bhubaneswar, India. (7)Peerless Diagnostic Centre, Kolkata, India. (8)Dr. Karmabir Chakravartty's Clinic, Kolkata, India. (9)Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. (10)All India Institute of Medical Sciences, Kalyani, West Bengal, India. (11)Institute of Child Health, Kolkata, India. BACKGROUND: As dysregulated gut microbiota is known in irritable bowel syndrome (IBS) and probiotics may improve it, we investigated the efficacy and safety of a combination probiotic, Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. lactis BB-12 in non-constipated IBS. METHODS: Two hundred non-constipated IBS patients were randomized to the above-mentioned probiotic and placebo for 84 days. The outcome measures included IBS-Global Improvement Scale (IBS-GIS), IBS-Quality of Life (IBS-QoL), EAR3Q, IBS-Severity Scoring System (IBS-SSS), and patient-reported improvement. Fecal microbiota was evaluated in a subset. RESULTS: Response in IBS-GIS was higher with probiotics than with placebo at days 28 (19.3% vs. 8.9%; p = 0.048), 56, and 84. Total and abdominal pain, distension, and QoL scores of IBS-SSS decreased at day 28 with probiotics that persisted till days 56 and 84. The percentage of patients with "severe" symptoms reduced from 20.8% at baseline to 3.9% at day 84, and the median IBS-QoL score decreased significantly at day 28; the beneficial effect on QoL was sustained till days 56 and 84 (p < 0.001). Improvement in abdominal pain, distension, urgency of defecation, bowel habit satisfaction, and stool frequency was noted earlier with probiotics than with placebo; 4.0% in the probiotic group and 0.9% in the placebo group had mild/moderate adverse events (p = 0.167). Symptom recurrence occurred in 3.0% in the probiotic group and 3.9% in the placebo group during follow-up of 180 days (p = 0.718). No difference was observed in the fecal microbiota between the two groups, but healthy genera were enriched with probiotics. CONCLUSIONS: The probiotic blend studied was more effective than placebo in non-constipated IBS in adults. © 2025 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. DOI: 10.1111/jgh.70137 PMID: 41255078 [Indexed for MEDLINE]
2. BMJ Open. 2025 Apr 2;15(4):e087934. doi: 10.1136/bmjopen-2024-087934. Study protocol for a randomised controlled trial evaluating the efficacy of dietary modulation of probiotics on nutritional status and antibody response to SARS-CoV-2 in Indonesian adolescents: gut-lung axis (DIVINE). Agustina R(1)(2), Ekawidyani KR(3)(4), Mutiyani M(3)(5), Prafiantini E(6)(2), Nindya TS(3)(7), Damayanti W(8), Rejeki PS(9), Djuari L(10), Huriyati E(11), Bines JE(12)(13)(14), Juffrie M(8). Author information: (1)Department of Nutrition, Faculty of Medicine - Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia r.agustina@ui.ac.id dr.rinaagustina@gmail.com. (2)Human Nutrition Research Center, Indonesian Medical Education and Research Institute (HNRC-IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. (3)Doctoral Study Program in Nutrition, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. (4)Department of Community Nutrition, Faculty of Human Ecology, IPB University, Bogor, West Java, Indonesia. (5)Department of Nutrition, Poltekkes Kemenkes Bandung, Bandung, West Java, Indonesia. (6)Department of Nutrition, Faculty of Medicine - Dr. Cipto Mangunkusumo General Hospital, Universitas Indonesia, Jakarta, Indonesia. (7)Department of Nutrition, Faculty of Public Health, Universitas Airlangga, Surabaya, East Java, Indonesia. (8)Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia. (9)Physiology Division, Department of Medical Physiology and Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia. (10)Department of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia. (11)Department of Nutrition and Health, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia. (12)Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia. (13)Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital Research Institute, Parkville, Victoria, Australia. (14)Murdoch Children's Research Institute, Parkville, Victoria, Australia. INTRODUCTION: During the pandemic, overweight and obese adolescents were at a higher risk of COVID-19 infection. Indonesia's government has implemented prevention programmes and immunisation; however, the rise in SARS-CoV-2 infections among adolescents is exacerbated by low-quality diet and lifestyle habits. Also, the vaccine programme is not prioritised in this population. To address this, a solution involves providing probiotics and counselling on healthy lifestyle habits to improve diet and immunity. Therefore, we designed a protocol for a randomised controlled trial with a 20-week intervention to investigate the effect of probiotics supplementation and counselling on healthy lifestyle habits, including healthy eating and physical activity, and psychosocial stimulation, on nutritional status and antibody response against SARS-CoV-2 in this group. METHODS AND ANALYSIS: This clinical trial aims to investigate the effects of probiotic supplementation on healthy overweight and obese adolescents. The study will involve 440 adolescents aged 12-17 living in Jakarta, Surabaya or Yogyakarta for at least 6 months and have completed at least two doses of the COVID-19 vaccine. The intervention group will receive daily probiotic supplementation of three strains, including Bifidobacterium animalis subsp. Lactis (BB-12), Lactobacillus acidophilus (LA-5) and Lactobacillus rhamnosus (LGG), at the level of 109-1010 colony-forming units for 20 weeks, while the control group will receive a placebo. Both groups will receive weekly counselling on healthy eating habits, physical activity and psychosocial stimulation. The primary outcomes will be changes in the body mass index for age z-score and IgG specific to SARS-CoV-2 titre concentrations between groups. The secondary outcomes will include changes in secretory IgA specific to SARS-CoV-2 titre concentrations, monoclonal antibodies against SARS-CoV-2 spike protein, gut microbiota diversity and the score of Healthy Eating Index 2015. ETHICS AND DISSEMINATION: The study protocol was approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital (KET 763/UN2.F1/ETIK/PPM.00.02/2022: 1 August 2022). The study results will be disseminated in open-access international journals, scientific meetings and conferences with stakeholders. TRIAL REGISTRATION NUMBER: The study has been registered at https://clinicaltrials.gov with identifier number NCT05623007. © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. DOI: 10.1136/bmjopen-2024-087934 PMCID: PMC11969610 PMID: 40180370 [Indexed for MEDLINE] Conflict of interest statement: Competing interests: None declared.
3. BMJ Open. 2024 Aug 29;14(8):e079526. doi: 10.1136/bmjopen-2023-079526. Effect of probiotic administration to breastfeeding mothers with very low birthweight neonates on some neonatal and maternal outcomes: study protocol for a randomised, double-blind, placebo-controlled trial. Alikamali M(1), Mohammad-Alizadeh-Charandabi S(2), Mirghafourvand M(3), Gharehbaghi MM(4), Homayouni-Rad A(5), Fardiazar Z(6), Shahnazi M(7). Author information: (1)Student Research Committee, Faculty of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran (the Islamic Republic of). (2)Faculty of Nursing and Midwifery, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran (the Islamic Republic of). (3)Faculty of Nursing and Midwifery, Social Determinants of Health Research Center, Department of Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran (the Islamic Republic of). (4)Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, Iran (the Islamic Republic of). (5)Faculty of Nutrition and Food Science, Department of Food Science and Technology, Tabriz University of Medical Sciences, Tabriz, Iran (the Islamic Republic of). (6)Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, Iran (the Islamic Republic of). (7)Faculty of Nursing and Midwifery, Department of Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran (the Islamic Republic of) shahnazimahnaz@gmail.com. INTRODUCTION: Premature birth and very low birth weight (VLBW) are leading causes of neonatal mortality. Almost all premature infants experience hyperbilirubinaemia. Administering probiotics to breastfeeding mothers may positively affect infant outcomes. This trial aims to investigate whether probiotic supplementation for mothers with VLBW infants affects total serum bilirubin levels and postpartum depression scores (primary outcomes), as well as some other neonatal and maternal outcomes (secondary outcomes). METHODS AND ANALYSIS: This is a randomised, double-blind, placebo-controlled superiority trial with two parallel arms. Participants, caregivers and outcome assessors will be blinded. A total of 122 breastfeeding mothers of neonates with a birth weight of 1000-1500 g, along with their infants within 48 hours of birth, will be assigned to either the probiotic or placebo group in a 1:1 ratio through block randomisation, stratified by singleton and twin births. The intervention will involve oral administration of probiotics containing Lactobacillus paracasei 431 and Bifidobacterium lactis BB-12, or an indistinguishable placebo, for 42-45 days. Outcomes will be assessed through daily observations, laboratory assessments and the Edinburgh Postpartum Depression Scale. Adverse events will also be documented. Modified intention-to-treat analyses will be employed for the primary and secondary outcomes, excluding participants lost to follow-up from all postintervention assessments. ETHICS AND DISSEMINATION: This study protocol has been approved by the Medical University of Tabriz Ethics Committee (IR.TBZMED.REC.1401.735). Findings will be disseminated through publication in a peer-reviewed journal and presentations at relevant conferences. TRIAL REGISTRATION NUMBER: IRCT20100414003706N42. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. DOI: 10.1136/bmjopen-2023-079526 PMCID: PMC11404231 PMID: 39209790 [Indexed for MEDLINE] Conflict of interest statement: Competing interests: None declared.
4. Nutr Neurosci. 2025 Apr;28(4):522-531. doi: 10.1080/1028415X.2024.2391655. Epub 2024 Aug 20. Effect of probiotics as an adjunctive therapy with Ritalin among ADHD children and adolescents: a triple-blind randomized controlled trial. Sangsefidi ZS(1), Sangsefidi ZS(2), Moharreri F(1), Heydari Yazdi AS(1), Eslami S(3)(4), Emadzadeh B(5), Ghorani B(5), Sarabi-Jamab M(6), Farahmand A(5), Modiri Dovom A(5), Ghanaei A(7), Emadzadeh M(8). Author information: (1)Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. (2)Department of Nutrition, School of Public Health, North Khorasan University of Medical Sciences, Bojnurd, Iran. (3)Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. (4)Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. (5)Department of Food Nanotechnology, Research Institute of Food Science and Technology (RIFST), Mashhad, Iran. (6)Department of Food Microbiology, Research Institute of Food Science and Technology (RIFST), Mashhad, Iran. (7)Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. (8)Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. OBJECTIVE: Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common mental disorders in children. Evidence regarding the impact of probiotics supplementation in ADHD children is limited and controversial. Thus, this study aimed to assess the effect of probiotics as an adjunctive therapy with Ritalin among ADHD children and adolescents. METHODS: This study was a triple-blind, randomized controlled trial of 60 Iranian ADHD patients aged four to sixteen. The participants were randomly assigned to receive probiotics supplements containing both Lactobacillus plantarum PTCC 1896™ (A7) and Bifidobacterium animalis subsp. Lactis (BB-12®) (n = 30) or placebo (n = 30) for 8 weeks. ADHD symptoms were assessed using Conners' Parent Rating Scale (CPRS) and Integrated Visual and Auditory Continuous Performance Test (IVA/CPT) at baseline and during the study. RESULTS: This study showed a significant decrease in the CPRS total score after 4 weeks of intervention in the probiotic group (baseline: 43.96 ± 21.52; fourth week: 37.22 ± 23.01; p = 0.01). However, no significant finding was found for the total score of the CPRS after 8 weeks. Moreover, at the end of the study, a significant increase was observed in score of auditory response control in the probiotic versus the placebo group (probiotic: 91.55 ± 16.69; placebo: 80.55 ± 17.43; p = 0.02). CONCLUSIONS: Probiotics supplementation with Ritalin may have some beneficial effects among ADHD children and adolescents, such as improving auditory response control and total score of CPRS. However, further clinical trials are required to clarify the impact of probiotics on ADHD. DOI: 10.1080/1028415X.2024.2391655 PMID: 39163291 [Indexed for MEDLINE]
5. JAMA Pediatr. 2024 Oct 1;178(10):985-995. doi: 10.1001/jamapediatrics.2024.2626. Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical Trial. Van Rossum T(1), Haiß A(2), Knoll RL(3)(4), Marißen J(2)(5), Podlesny D(1), Pagel J(2)(6), Bleskina M(7), Vens M(7), Fortmann I(2), Siller B(2), Ricklefs I(2), Klopp J(3), Hilbert K(3), Meyer C(3), Thielemann R(1), Goedicke-Fritz S(8), Kuntz M(9), Wieg C(10), Teig N(11), Körner T(12), Kribs A(13), Hudalla H(14), Knuf M(15)(16), Stein A(17), Gille C(14)(18), Bagci S(19), Dohle F(20), Proquitté H(21), Olbertz DM(22), Schmidt E(23), Koch L(24), Pirr S(25), Rupp J(26)(27), Spiegler J(2)(5), Kopp MV(2)(28), Göpel W(2), Herting E(2), Forslund SK(1)(4), Viemann D(5)(25), Zemlin M(8)(29)(30), Bork P(1), Gehring S(3), König IR(7), Henneke P(9)(31)(32), Härtel C(2)(5)(27). Author information: (1)European Molecular Biology Laboratory, Heidelberg, Germany. (2)Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. (3)Department of Pediatrics, University Hospital Mainz, Mainz, Germany. (4)Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany. (5)Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany. (6)Department of Pediatrics, University Hospital Hamburg-Eppendorf, Hamburg-Eppendorf, Germany. (7)Institute for Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany. (8)Department of General Pediatrics and Neonatology, Saarland University Homburg, Germany. (9)Department of Pediatrics, University of Freiburg, Freiburg, Germany. (10)Children's Hospital Aschaffenburg-Alzenau, Aschaffenburg, Germany. (11)Department of Pediatrics, University of Bochum, Bochum, Germany. (12)Children's Hospital Mitte Bremen, Bremen, Germany. (13)Department of Pediatrics, University of Cologne, Cologne, Germany. (14)Department of Neonatology, University of Heidelberg, Heidelberg, Germany. (15)Children's Hospital Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany. (16)Children's Hospital Worms, Worms, Germany. (17)Department of Pediatrics I, University of Duisburg-Essen, Duisburg-Essen, Germany. (18)Department of Neonatology, University of Tübingen, Tübingen, Germany. (19)Department of Neonatology, University of Bonn, Bonn, Germany. (20)Children's Hospital Paderborn, Paderborn, Germany. (21)Department of Neonatology, University of Jena, Jena, Germany. (22)Department of Neonatology, Hospital Rostock Südstadt, University of Rostock, Rostock, Germany. (23)Helios Children's Hospital Schwerin, Schwerin, Germany. (24)Children's Hospital Hamburg Wilhelmstift and Marien-Hospital Hamburg, Medical School Hamburg, Hamburg, Germany. (25)Department of Neonatology, Allergology and Pediatric Pneumology, Hannover Medical School, Hannover, Germany. (26)Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany. (27)German Center of Infectious Diseases Research, Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany. (28)Department of Pediatrics, University Hospital of Berne, Berne, Switzerland. (29)Center for Genderspecific Biology and Medicine, Saarland University Homburg, Homburg, Germany. (30)Center vor Digital Neurotechnologies Saar, Saarland University Homburg, Homburg, Germany. (31)Institute for Immunodeficiency, Centre for Chronic Immunodeficiency, University Medical Centre and Faculty of Medicine, University of Freiburg, Freiburg, Germany. (32)Institute for Infection Prevention and Control, University Medical Centre and Faculty of Medicine, University of Freiburg, Freiburg, Germany. IMPORTANCE: The effects of probiotic interventions on colonization with resistant bacteria and early microbiome development in preterm infants remain to be clarified. OBJECTIVE: To examine the efficacy of Bifidobacterium longum subsp infantis, Bifidobacterium animalis subsp lactis (BB-12), and Lactobacillus acidophilus (La-5) probiotics to prevent colonization with multidrug-resistant organisms or highly epidemic bacteria (MDRO+) and to shape the microbiome of preterm infants toward the eubiotic state of healthy full-term infants. DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blinded, placebo-controlled, group sequential, phase 3 Priming Immunity at the Beginning of Life (PRIMAL) randomized clinical trial, conducted from April 2018 to June 2020, included infants with gestational age of 28 to 32 weeks at 18 German neonatal units. Data analyses were conducted from March 2020 to August 2023. INTERVENTION: A total of 28 days of multistrain probiotics diluted in human milk/formula starting within the first 72 hours of life. MAIN OUTCOMES AND MEASURES: Colonization with MDRO+ at day 30 of life (primary end point), late-onset sepsis and severe gastrointestinal complication (safety end points), and gut dysbiosis, ie, deviations from the microbiome of healthy, term infants (eubiosis score) based on 16-subunit ribosomal RNA and metagenomic sequencing. RESULTS: Among the 643 infants randomized until the stop of recruitment based on interim results, 618 (median [IQR] gestational age, 31.0 [29.7-32.1] weeks; 333 male [53.9%]; mean [SD] birth weight, 1502 [369] g) had follow-up at day 30. The interim analysis with all available data from 219 infants revealed MDRO+ colonization in 43 of 115 infants (37.4%) in the probiotics group and in 39 of 104 infants (37.5%) in the control group (adjusted risk ratio, 0.99; 95% CI, 0.54-1.81; P = .97). Safety outcomes were similar in both groups, ie, late-onset sepsis (probiotics group: 8 of 316 infants [2.5%]; control group: 12 of 322 infants [3.7%]) and severe gastrointestinal complications (probiotics group: 6 of 316 infants [1.9%]; control group: 7 of 322 infants [2.2%]). The probiotics group had higher eubiosis scores than the control group at the genus level (254 vs 258 infants; median scores, 0.47 vs 0.41; odds ratio [OR], 1.07; 95% CI, 1.02-1.13) and species level (96 vs 83 infants; median scores, 0.87 vs 0.59; OR, 1.28; 95% CI, 1.19-1.38). Environmental uptake of the B infantis probiotic strain in the control group was common (41 of 84 [49%]), which was highly variable across sites and particularly occurred in infants with a sibling who was treated with probiotics. CONCLUSIONS AND RELEVANCE: Multistrain probiotics did not reduce the incidence of MDRO+ colonization at day 30 of life in preterm infants but modulated their microbiome toward eubiosis. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00013197. DOI: 10.1001/jamapediatrics.2024.2626 PMCID: PMC12549143 PMID: 39102225 [Indexed for MEDLINE] Conflict of interest statement: Conflict of Interest Disclosures: Dr Klopp reported receiving grants from German Ministry of Education and Research during the conduct of the study. Dr Kuntz reported receiving grants from the German Ministry of Education and Research during the conduct of the study. Dr Kribs reported receiving lecture fees from Chiesi outside the submitted work. Dr Stein reported receiving grants from Universitätsklinikum Schleswig Holstein to support data acquisition and lecture fees from Chiesi outside the submitted work. Dr Gille reported receiving grants from the Federal Ministry of Education and Research and the German Center for Infection Research outside the submitted work; in addition, Dr Gille reported having a patent for US 11,591,568 B2 licensed. Dr Pirr reported receiving grants from the German Ministry of Education and Research and the Deutsche Forschungsgemeinschaft outside the submitted work. Dr Kopp reported receiving grants from the University of Bern and personal fees from Infectopharm GmbH, Allergopharma GmbH, and Sanofi GmbH outside the submitted work. Dr Göpel reported receiving grants from German Ministry of Education and Research for the PRIMAL study during the conduct of the study. Dr Herting reported receiving grants from Klinik für Kinder und Jugendmedizin, the University of Lübeck, and the German Government. Dr Zemlin reported receiving grants from BMBF during the conduct of the study. Dr König reported receiving grants from German Ministry of Education and Research during the conduct of the study. Dr Henneke reported receiving grants from BMBF, German Research Council, and the Else-Kröner Foundation and personal fees from BioNTech and GSK outside the submitted work. Dr Härtel reported receiving lecture fees from Chiesi and being involved in national and international guidelines related to neonatal infection. No other disclosures were reported.
6. Nutrients. 2024 Jan 25;16(3):349. doi: 10.3390/nu16030349. Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review and Practical Insights. Salvatore S(1), Carlino M(2), Sestito S(2), Concolino D(2), Agosti M(1), Pensabene L(2). Author information: (1)Pediatric Department, Hospital "F. Del Ponte", University of Insubria, 21100 Varese, Italy. (2)Pediatric Unit, Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy. Different nutraceuticals are often considered by parents of infants and children with abdominal pain and disorders of the gut-brain interaction. Herb extracts and natural compounds have long been used in traditional medicine, but clinical pediatric trials are very limited. This narrative review based on relevant studies identified through a search of the literature in Pubmed and Medline updated to October 2023 focused on the effect of nutraceuticals in infantile colic, functional abdominal pain, and irritable bowel syndrome in children and adolescents. Significant reductions in colic episodes and crying time were reported in two studies on fennel (seeds oil or tea), in three studies on different multiple herbal extracts (all including fennel), in one study on Mentha piperita, and in at least two double-blind randomized controlled studies on Lactobacillus reuteri DSM 17938 and Bifidobacterium lactis BB-12 (108 CFU/day for at least 21 days) in breast-fed infants. Compared to a placebo, in children with functional abdominal pain or irritable bowel syndrome, a significant reduction in pain was reported in two studies supplementing peppermint oil capsules or psyllium fibers, and in one study on corn fiber cookies, partial hydrolyzed guar gum, a specific multiple herbal extract (STW-5), or vitamin D supplementation. To date, there is moderate-certainty evidence with a weak grade of recommendation on Lactobacillus reuteri DSM 17938 (108 CFU/day) in reducing pain intensity in children with functional abdominal pain and for Lactobacillus rhamnosus GG (1-3 × 109 CFU twice daily) in reducing pain frequency and intensity in children with IBS. Further large and well-designed pediatric studies are needed to prove the efficacy and safety of different herbal extracts and prolonged use of studied products in infants and children with pain disorders of the gut-brain interaction. DOI: 10.3390/nu16030349 PMCID: PMC10856962 PMID: 38337634 [Indexed for MEDLINE] Conflict of interest statement: The authors have no conflicts of interest to declare.
7. Turk J Gastroenterol. 2022 Nov;33(11):925-933. doi: 10.5152/tjg.2022.211063. Metformin with Versus without Concomitant Probiotic Therapy in Newly Diagnosed Patients with Type 2 Diabetes or Prediabetes: A Comparative Analysis in Relation to Glycemic Control, Gastrointestinal Side Effects, and Treatment Compliance. Şahin K(1), Şahintürk Y(1), Köker G(1), Özçelik Köker G(1), Bostan F(1), Kök M(1), Uyar S(1), Çekin AH(1). Author information: (1)Department of Internal Medicine, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey. BACKGROUND: To evaluate the impact of concomitant use of probiotic BB-12 in metformin-treated patients with type 2 diabetes or prediabetes on glycemic control, metformin-related gastrointestinal side effects, and treatment compliance. METHODS: A total of 156 patients (mean [standard deviation] age: 50.9 [9.9 years], 74.4% females) with newly diagnosed type 2 diabetes or prediabetes were randomly assigned to receive either metformin alone (n = 84, MET group) or metformin plus Bifidobacterium animalis subsp. lactis (BB-12) probiotic (n = 72, MET-PRO group). Data on body mass index (kg/m2), fasting blood glucose (mg/dL), blood lipids, and glycated hemoglobin (HbA1c) levels were recorded at baseline and at the third month of therapy. Data on gastrointestinal intolerance symptoms and treatment noncompliance were also recorded during post-treatment week 1 to week 4. RESULTS: MET-PRO versus MET therapy was associated with a significantly higher rate of treatment compliance (91.7% vs 71.4%, P = .001), greater reduction from baseline HbA1c values (0.9 [0.4-1.6] vs 0.4 [0-1.6] %, P < .001) and lower likelihood of gastrointestinal intolerance symptoms, including abdominal pain (P = .031 to <.001), diarrhea (P = .005 to <.001) and bloating (P = .010 to <.001). Noncompliance developed later (at least 15 days after the therapy) in a significantly higher percentage of patients in the MET group (P = .001 for 15-21 days and P = .002 for 22-28 days). CONCLUSION: In conclusion, the present study proposes the benefit of combining probiotics with metformin in the treatment of patients with T2D or prediabetes in terms of improved glycemic control and treatment adherence rather than correction of dyslipidemia or weight reduction. DOI: 10.5152/tjg.2022.211063 PMCID: PMC9797791 PMID: 36098362 [Indexed for MEDLINE]
8. Nutrients. 2022 Jun 24;14(13):2620. doi: 10.3390/nu14132620. A Four-Probiotic Regime to Reduce Surgical Site Infections in Multi-Trauma Patients. Tzikos G(1), Tsalkatidou D(1), Stavrou G(2)(3), Thoma G(4), Chorti A(1), Tsilika M(5), Michalopoulos A(1), Papavramidis T(1), Giamarellos-Bourboulis EJ(5), Kotzampassi K(2). Author information: (1)1st Propedeutic Department of Surgery, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece. (2)Department of Surgery, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece. (3)Leeds Institute of Emergency General Surgery, Leeds Teaching Hospitals NHS Trust, Leeds LS97LS, UK. (4)Intensive Care Unit, Aghios Pavlos General Hospital, 55134 Thessaloniki, Greece. (5)4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 12462 Athens, Greece. Investigations that focused on the protective role of probiotics against Surgical Site Infections (SSI) in multiple-trauma (MT) patients are generally few, probably due to the complexity of the concept of trauma. We aimed to assess the efficacy of a four-probiotic regime to reduce the incidence of SSI in MT patients, with a brain injury included. MT patients, being intubated and expected to require mechanical ventilation for >10 days, were randomly allocated into placebo (n = 50) or probiotic treatment (n = 53) comprising Lactobacillus acidophilus LA-5 (1.75 × 109 cfu), Lactiplantibacillus plantarum UBLP-40 (0.5 × 109 cfu), Bifidobacterium animalis subsp. lactis BB-12 (1.75 × 109 cfu), and Saccharomycesboulardii Unique-28 (1.5 × 109 cfu) in sachets. All patients received two sachets of placebo or probiotics twice/day for 15 days and were followed-up for 30 days. The operations were classified as neurosurgical, thoracostomies, laparotomies, orthopedics, and others; then, the SSI and the isolated pathogen were registered. A total of 23 (46.0%) and 13 (24.5%) infectious insults in 89 (50 placebo patients) and 88 (53 probiotics-treated) operations (p = 0.022) were recorded, the majority of them relating to osteosynthesis—17 and 8, respectively. The most commonly identified pathogens were Staphylococcus aureus and Acinetobacter baumannii. Our results support published evidence that the prophylactic administration of probiotics in MT patients exerts a positive effect on the incidence of SSI. DOI: 10.3390/nu14132620 PMCID: PMC9268677 PMID: 35807801 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.
9. J Indian Soc Pedod Prev Dent. 2021 Oct-Dec;39(4):416-422. doi: 10.4103/jisppd.jisppd_236_21. A comparative evaluation of probiotic formulations in prevention of dental caries: A clinical study. Sakhare S(1), Shantanu C(2), Mopagar V(3), Hadpe HS(3), Choughule K(4), Dahapute S(5), Shetty S(6), Joshi S(3). Author information: (1)Department of Pediatric & Preventive Dentistry, Vasantdada Patil Dental College, Sangali, Maharastra, India. (2)Department of Pediatric and Preventive Dentistry, Government Dental College, Ahmedabad, Gujarat, India. (3)Department of Pediatric and Preventive Dentistry, Rural Dental College, Loni, Rahata, Maharastra, India. (4)Department of Orthodontics, TKDC, Kolhapur, Maharastra, India. (5)Department Of Orthodontics, TKDC, Kolhapur, Maharastra, India. (6)Department of Pediatric and Preventive Dentistry, Yogita Dental College, Ratnagiri, Maharastra, India. BACKGROUND: Caries is a multifactorial disease, microbes being an important etiological factor. "Probiotics" are nonpathogenic microbes which can stimulate health-promoting flora and suppress pathogens. It's the era of prevention, clinical approach toward prevention by altering bacterial ecology is the need of the hour. The aim of the study was to evaluate anticariogenic effect of probiotic curd (Amul's Probiotic Dahi) containing Lactobacillus acidophilus (La5) and Bifidobacterium lactis (Bb12) in 6-12 years of age group. MATERIALS AND METHODS: This was a prospective, randomized, nonblinded study conducted on school children aged between 6 and 12 years having Decayed, Missing, and Filled Teeth and/or deft ≥2. Selected subjects were divided into two groups of 31 each, study group received probiotic curd ("Amul's Probiotic Dahi") two times a day in a quantity of 100 g, respectively, for 21 days and control group did not receive any intervention. Salivary Streptococcus mutans count and salivary pH estimation were done at the baseline, after 7 days and at the end after 24 days, for comparison. RESULTS: No statistical difference was seen in salivary S. mutans count between both groups, after intervention of 7 days. However, there was significant difference in salivary S. mutans count at the end of 24 days. There was no statistical difference in salivary pH between both groups. CONCLUSION: The present study concludes that probiotics substitute decreases salivary S. mutans count after continuous consumption for 3 weeks and there is no short-term effect on salivary pH. DOI: 10.4103/jisppd.jisppd_236_21 PMID: 35102968 [Indexed for MEDLINE] Conflict of interest statement: None
10. Benef Microbes. 2021 Nov 16;12(6):531-540. doi: 10.3920/BM2020.0233. Epub 2021 Sep 22. Efficacy of Bifidobacterium animalis subsp. lactis, BB-12(®) on infant colic - a randomised, double-blinded, placebo-controlled study. Chen K(1)(2), Zhang G(3), Xie H(4), You L(5), Li H(6), Zhang Y(7), Du C(8), Xu S(9), Melsaether C(10), Yuan S(1). Author information: (1)Department of Nutrition, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617, Riyue Avenue, Qingyang District, Chengdu, 6100131, China P.R. (2)Department of Child Health Care, Chengdu New Century Women's and Children's Hospital, No.77, Baojia Lane, Qingyang District, Chengdu, China P.R. (3)Department of Pediatric Intensive Care Unit, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617, Riyue Avenue, Qingyang District, Chengdu, China P.R. (4)Department of Pediatrics, Dayi Maternal and Child Health Care Hospital, No. 539, Inner Mongolia Avenue, Jinyuan Town, Dayi County, Chengdu, China P.R. (5)Department of Child Health Care, Nanxin Community Health Service Center, N0. 168, Guanghe 1st Street, Wuhou District, Chengdu, China P.R. (6)Department of Child Health Care, Qingbaijiang Maternal and Child Health Care Hospital, No.87, Qingjiang South Road, Qingbaijiang District, Chengdu, China P.R. (7)Department of Child Health Care, Jinniu Maternal and Child Health Care Hospital, No.12, Changyue Road, Jinniu District, Chengdu, China P.R. (8)Department of Child Health Care, Longquanyi Maternal and Child Health Care Hospital, No.383, Yuyang Road, Longquanyi District, Chengdu, China P.R. (9)Department of Child Health Care, Huili Maternal and Child Health Care Hospital, No. 41, Jindai Road West Section, Guoyuan Township, Huili County, Xichang, China P.R. (10)Chr. Hansen A/S, HH Clinical Development, Kogle Alle 6, 2970 Hoersholm, Denmark. To evaluate the administration of Bifidobacterium animalis subsp. lactis, BB-12® (BB-12) on infant colic in breastfed infants, a double-blind, placebo-controlled randomised study was conducted in Chengdu, China from April 2016 to October 2017 with 192 full-term infants less than 3 months of age and meeting the ROME III criteria for infant colic. After a 1-week run-in the infants were randomly assigned to receive daily BB-12 (1×109 cfu/day) or placebo for 3 weeks. Crying/fussing time were recorded using a 24 h structured diary. The primary endpoint was the proportion of infants achieving a reduction in crying and fussing time of ≥50% from baseline. Parent's/caregiver's health related quality of life was measured using a modified PedsQL™ 2.0 Family Impact Module and immunological biomarkers were evaluated from faecal samples at baseline and after the 21-day intervention. The percentage of infants achieving a reduction in the daily crying/fussing time ≥50% after the 21-day intervention was significantly higher in the infants supplemented with BB-12 (P<0.001). The mean number of crying episodes was significantly reduced in the BB-12 group compared to the placebo group (10.0±3.0 to 5.0±1.87 vs 10.5±2.6 to 7.5±2.8, respectively) (P<0.001) and the mean daily sleep duration was markedly increased from baseline to end of intervention in the BB-12 group compared to the infants in the placebo group (60.7±104.0 vs 31.9±102.7 min/day, respectively) (P<0.001). The faecal levels of human beta defensin 2, cathelicidin, slgA, calprotectin and butyrate were statistically higher in the BB-12 group compared to the placebo group after the 21-day intervention. At the end of the intervention the parent's/caregiver's physical, emotional and social functioning scores were significantly higher for the BB-12 group compared to the placebo group (all P<0.05). Supplementation of BB-12 is effective in reducing crying and fussing in infants diagnosed with infant colic. DOI: 10.3920/BM2020.0233 PMID: 34550055 [Indexed for MEDLINE]
11. Nutrients. 2021 Aug 17;13(8):2814. doi: 10.3390/nu13082814. Bifidobacterium animalis subsp. lactis BB-12 Protects against Antibiotic-Induced Functional and Compositional Changes in Human Fecal Microbiome. Merenstein D(1)(2), Fraser CM(3), Roberts RF(4), Liu T(5), Grant-Beurmann S(3), Tan TP(1), Smith KH(1), Cronin T(1), Martin OA(3)(6), Sanders ME(7), Lucan SC(8), Kane MA(5). Author information: (1)Department of Family Medicine, Georgetown University Medical Center, Washington, DC 20057, USA. (2)Department of Human Science, School of Nursing and Health Studies, Georgetown University Medical Center, Washington, DC 20057, USA. (3)Institute for Genomic Sciences, Departments of Medicine and Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. (4)Department of Food Science, The Pennsylvania State University, University Park, PA 16802, USA. (5)Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA. (6)Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA. (7)Dairy & Food Culture Technologies, Centennial, CO 80122, USA. (8)Department of Family and Social Medicine, Albert Einstein College of Medicine, Montefiore Health System, Bronx, NY 10461, USA. The administration of broad-spectrum antibiotics is often associated with antibiotic-associated diarrhea (AAD), and impacts gastrointestinal tract homeostasis, as evidenced by the following: (a) an overall reduction in both the numbers and diversity of the gut microbiota, and (b) decreased short-chain fatty acid (SCFA) production. Evidence in humans that probiotics may enhance the recovery of microbiota populations after antibiotic treatment is equivocal, and few studies have addressed if probiotics improve the recovery of microbial metabolic function. Our aim was to determine if Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-containing yogurt could protect against antibiotic-induced fecal SCFA and microbiota composition disruptions. We conducted a randomized, allocation-concealed, controlled trial of amoxicillin/clavulanate administration (days 1-7), in conjunction with either BB-12-containing or control yogurt (days 1-14). We measured the fecal levels of SCFAs and bacterial composition at baseline and days 7, 14, 21, and 30. Forty-two participants were randomly assigned to the BB-12 group, and 20 participants to the control group. Antibiotic treatment suppressed the fecal acetate levels in both the control and probiotic groups. Following the cessation of antibiotics, the fecal acetate levels in the probiotic group increased over the remainder of the study and returned to the baseline levels on day 30 (-1.6% baseline), whereas, in the control group, the acetate levels remained suppressed. Further, antibiotic treatment reduced the Shannon diversity of the gut microbiota, for all the study participants at day 7. The magnitude of this change was larger and more sustained in the control group compared to the probiotic group, which is consistent with the hypothesis that BB-12 enhanced microbiota recovery. There were no significant baseline clinical differences between the two groups. Concurrent administration of amoxicillin/clavulanate and BB-12 yogurt, to healthy subjects, was associated with a significantly smaller decrease in the fecal SCFA levels and a more stable taxonomic profile of the microbiota over time than the control group. DOI: 10.3390/nu13082814 PMCID: PMC8398419 PMID: 34444974 [Indexed for MEDLINE] Conflict of interest statement: MES has been compensated for speaking engagements or for consulting from Associated British Foods, California Dairy Research Foundation, Church & Dwight, Danone North America, Fairlife, GlaxoSmithKline, Kerry, Mead Johnson, PepsiCo, and Trouw Nutrition. She has served on scientific advisory boards for Cargill, Sanofi, Danone North America, Danone Research, Winclove Probiotics and Yakult. She serves as the executive science officer for the International Scientific Association for Probiotics and Prebiotics. DM has consulted for Bayer & Pfizer. SCL has been compensated both for speaking engagements and for serving on the Scientific and Nutritional Advisory Board of Epicure. SCL has also consulted for Danone North America. The other authors have no competing interests to declare. None of the companies listed above had any role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Additionally none have seen the results.
12. mSphere. 2021 Aug 25;6(4):e0008421. doi: 10.1128/mSphere.00084-21. Epub 2021 Jul 7. Matrix Effects on the Delivery Efficacy of Bifidobacterium animalis subsp. lactis BB-12 on Fecal Microbiota, Gut Transit Time, and Short-Chain Fatty Acids in Healthy Young Adults. Ba Z(1), Lee Y(2), Meng H(2), Kris-Etherton PM(2), Rogers CJ(2), Lewis ZT(3), Mills DA(3), Furumoto EJ(1), Rolon ML(1), Fleming JA(2), Roberts RF(1). Author information: (1)Department of Food Science, The Pennsylvania State Universitygrid.29857.31, University Park, Pennsylvania, USA. (2)Department of Nutritional Sciences, The Pennsylvania State Universitygrid.29857.31, University Park, Pennsylvania, USA. (3)Department of Food Science and Technology, University of California, Davis, California, USA. Probiotics are consumed in fermented dairy products or as capsules for their putative health benefits. However, little research has been done to evaluate the effects of the delivery matrix on the health benefits of probiotics in humans. To examine the effects of delivering Bifidobacterium animalis subsp. lactis BB-12 (BB-12) (log10 10 ± 0.5 CFU/day) via a yogurt smoothie versus a capsule, we monitored the fecal microbiota, gut transit times (GTTs), and fecal excretion of short-chain fatty acids (SCFAs) in healthy adults. In a randomized, four-period, crossover study performed in a partially blind manner, 36 adults were recruited and randomly assigned to four treatments: control yogurt smoothie (YS), yogurt smoothie with BB-12 added prefermentation (PRE), yogurt smoothie with BB-12 added postfermentation (POST), and capsule containing BB-12 (CAP). Participants' fecal microbiota was assessed using 16S rRNA sequencing, GTTs via SmartPill, and fecal SCFAs by gas chromatography (GC) before (baseline) and after each intervention. Participants had significantly higher percentage of Streptococcus after consuming YS versus CAP (P = 0.01). Bifidobacterium-specific terminal restriction fragment length polymorphism analysis revealed a significantly higher percentage of B. animalis after consuming PRE and POST compared to baseline, YS, CAP, and final washout (P < 0.0001). The predominant SCFAs were negatively correlated with GTTs. Consumption of BB-12 delivered in a yogurt smoothie or capsule did not significantly alter the composition of the gut microbiota, GTTs, or fecal SCFA concentration of the study cohort. However, daily consumption of BB-12 in yogurt smoothie may result in higher relative abundance of B. animalis in healthy adults. (This trial has been registered at ClinicalTrials.gov under identifier NCT01399996.) IMPORTANCE Bifidobacterium animalis subsp. lactis BB-12 is a probiotic strain that has been used worldwide since 1985. It has commonly been delivered in fermented dairy products for perceived benefits associated with gut health and enhanced immune function. In addition to fermented dairy products, many new probiotic-containing alternatives such as probiotic-containing juice, probiotic-containing chocolate, and capsules have been developed. While these products provide more options for people to access probiotics, little research has been done on the effect of delivery matrix (dairy versus nondairy) on their efficacy in humans. In addition, it was unclear how yogurt fermentation may influence the survival of BB-12 in the product or on its performance in vivo. The significance of our study is in simultaneously assessing the effect of BB-12, alone and in different delivery vehicles, on the gut transit time, fecal short-chain fatty acids, and the composition of the gut microbiota of the study cohort. DOI: 10.1128/mSphere.00084-21 PMCID: PMC8386398 PMID: 34232082 [Indexed for MEDLINE]
⚠️ 면책 고지
이 정보는 일반 교육 목적이며 의료 진단/처방을 대체하지 않습니다.